Skip to main content
Premium Trial:

Request an Annual Quote

AssureRx Secures $8M Credit Facility

NEW YORK (GenomeWeb News) – AssureRx today announced it has secured an $8 million term and revolving credit facility, which it will use to increase adoption of its GeneSightRx test.

The facility was secured through the Mason, Ohio-based firm's new banking partner, Silicon Valley Bank. In addition to ramping up GeneSightRx, AssureRx said that the financing will be used to finance new products anticipated to launch this year.

It also plans to "substantially" increase the size of its sales force in 2012.

GeneSightRx, launched in 2009, is a pharmacogenomic test for helping clinicians determine which psychiatric drugs may be most effective for a specific patient. The company received certification from New York last week for its laboratory, and can now analyze DNA analysis for pharmacogenomic testing in all 50 states.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.